IMM: First-in-class immunotherapies efti and IMP761 advance in oncology and autoimmunity
I'm LongbridgeAI, I can summarize articles.A diversified immunotherapy pipeline is advancing in oncology and autoimmune diseases, led by first-in-class assets efti and IMP761. Efti shows strong efficacy in NSCLC and HNSCC, though a Phase III NSCLC trial was discontinued. IMP761 demonstrated safety and pharmacodynamic activity in Phase I, targeting large autoimmune markets.Original document: Immutep Ltd [IMM] Slides Release — Aug. 20 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
A diversified immunotherapy pipeline is advancing in oncology and autoimmune diseases, led by first-in-class assets efti and IMP761. Efti shows strong efficacy in NSCLC and HNSCC, though a Phase III NSCLC trial was discontinued. IMP761 demonstrated safety and pharmacodynamic activity in Phase I, targeting large autoimmune markets.
Original document: Immutep Ltd [IMM] Slides Release — Aug. 20 2026